Context Therapeutics Azioni (NASDAQ: CNTX)

Ultime notizie per Context Therapeutics (NASDAQ:CNTX) Azioni

Context Therapeutics

Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.

Context Therapeutics Inc

VANCOUVER, BC, April 17, 2025 /CNW/ - Finlay Minerals Ltd. (TSXV:<a class="ticker" href="https://www.benzinga.com/stock/FYL#TSXV">FYL</a>) (OTCQB:<a class="ticker" href="https://www.benzinga.com/stock/FYMNF#OTCQB">FYMNF</a>) ("Finlay" or the "Company") announces that the Company has entered into two definitive earn-in agreements (the "Earn-In Agreements") with Freeport-McMoRan Mineral Properties Canada Inc. ("Freeport"), a wholly owned subsidiary of Freeport-McMoRan Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FCX#NYSE">FCX</a>), pursuant to which it has granted Freeport separate options to earn an 80% interest in its PIL and ATTY Properties (the "Properties") in the Toodoggone District of northern British Columbia.
Highlights –
<ul>
<li>Freeport may earn 80% of the&nbsp;PIL and ATTY Projects by expending $35 million in Exploration Expenditures and making Cash Payments of $4.1 million - (Refer to Table 1 below for further details);</li>
<li>Finlay will act as the Operator during the Earn-In period; and</li>
<li>Exploration Program planning is underway and will be announced shortly.</li>
</ul>

News

FYMNF

TSXV:FYL

Finlay Minerals Enters Into Two Definitive Earn-in Agreements With Freeport-McMoRan Subsidiary Freeport-mcmoran Mineral Properties Canada

Analyst Ratings

Trading Ideas

NFLX

Live On CNBC, Bill Baruch Announces Bought Netflix

Tilray Brands Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLRY#NASDAQ">TLRY</a>) shares slipped 6.8% on Thursday afternoon after the <a href="https://www.benzinga.com/cannabis">cannabis</a> and beverage company proposed a reverse stock split that would significantly reduce its number of shares outstanding.
In a notice to investors, <a href="https://www.benzinga.com/topic/tilray">Tilray</a> said it would hold a special shareholder meeting on June 10 to vote on amending its certificate of incorporation to enable a reverse split in a range of 1-for-10 to 1-for-20. The exact ratio would be selected by the company's board.
CEO Irwin Simon framed the move as part of a broader effort to maintain Tilray's Nasdaq listing, stabilize share prices, attract institutional investors, and reduce administrative costs.
"A higher price per share would ensure compliance with Nasdaq&#8217;s continued listing requirements and places Tilray in a position to continue executing on our strategic plans," Simon said in a statement. "We expect this decision to aid in the Company's efforts to stabilize trading levels, attract and retain institutional shareholders, and decrease our cost structure by over $1 million on an annual run rate basis."
While reverse stock splits can help struggling stocks regain compliance or investor attention, they often trigger short-term selloffs due to concerns about dilution or underlying financial health.
Also read: <a href="https://www.benzinga.com/news/earnings/25/04/44802163/why-cannabis-focused-biopharma-co-avicanna-traded-up-26-today">Why Cannabis-Focused Biopharma Co. Avicanna Traded Up 26%+ Today</a>
Despite Tuesday's drop, Tilray emphasized its improved financial position, citing a $76 million reduction in debt year-to-date and a cash and marketable securities balance of over $248 million as of February 28, 2025. The company says its net debt to EBITDA ratio is now below 1.0x, a strong sign of fiscal stability.
In a separate announcement Tuesday, Tilray also shared that it has expanded its medical cannabis product line in Australia, launching Good Supply Pastilles — its first edibles offering for patients in that market. The sugar-free, vegan-friendly products come in THC10, THC10:CBD10, and CBD20 varieties.
"The expansion of our medical cannabis portfolio with the introduction of Good Supply Pastilles in Australia is a significant milestone," said Denise Faltischek, Tilray's chief strategy officer and head of international. "We are committed to providing high-quality, accessible medical cannabis products in convenient formats to patients worldwide."
Photo: Shutterstock

Cannabis

TLRY

Why Cannabis Co. Tilray (TLRY) Is Trading Down Today

HC Wainwright &amp; Co. analyst Joseph Pantginis reiterates Viking Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VKTX#NASDAQ">VKTX</a>) with a Buy and maintains $102 price target.

Price Target

Reiteration

VKTX

HC Wainwright & Co. Reiterates Buy on Viking Therapeutics, Maintains $102 Price Target

Blackstone, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BX#NYSE">BX</a>) president Jonathan Gray cautioned on Thursday that ongoing uncertainty around President Donald Trump's tariff policies heightens the<a href="https://www.benzinga.com/news/global/25/04/44860334/china-cuts-us-oil-purchases-by-90-boosts-imports-from-canada-to-new-heights"> risk of a recession.&nbsp;</a>
What To Know: Gray, who oversees daily operations at the investment giant, warned that the longer global tariff uncertainty persists, the greater the chance for market disorder and unintended consequences throughout the financial system.
Read Next:<a href="https://www.benzinga.com/general/health-care/25/04/44869920/unitedhealth-ceo-says-high-cost-of-us-health-care-simply-not-sustainable"> UnitedHealth CEO Says High Cost Of US Health Care &#8216;Simply Not Sustainable&#8217;&nbsp;</a>
"I would expect an economic slowdown. How significant the economic slowdown is will be directly correlated to the length of the tariff diplomacy," Gray said, according to a Financial Times<a href="https://www.ft.com/content/1326ad5e-f44f-40ca-aa07-3a619fe633c7"> report</a>.&nbsp;
"The recession risk is directly tied to the length of the uncertainty," the Blackstone president said, adding that a quick resolution to trade negotiations would be "positive for the economy and markets."
Gray's comments align with other financial leaders who have called for swift resolution to trade disputes, warning that prolonged uncertainty could undermine confidence and growth. JPMorgan Chase &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JPM#NYSE">JPM</a>) CEO Jamie Dimon recently predicted a recession as a &#8220;likely outcome&#8221; due to the tariffs and said the resulting economic uncertainty could have lasting negative consequences.&nbsp;
&#8220;Take a deep breath, negotiate some trade deals," Dimon urged the Trump administration last week. "It could get worse if we don&#8217;t make progress."
Despite the turbulence, Blackstone reported strong first-quarter <a href="https://www.benzinga.com/25/04/44862568/blackstone-beats-q1-estimates-aum-climbs-to-117t-inflows-hit-3-year-high">financial results</a> on Thursday morning with inflows reaching $62 billion, the highest level in three years.&nbsp;
Blackstone CEO Stephen A. Schwarzman implied, in prepared remarks included with the earnings release, that the firm was prepared to take advantage of the current market volatility.&nbsp;
"We are well positioned to navigate the current environment with $177 billion of dry powder to deploy and a resilient, capital-light business model," Schwarzman said.&nbsp;
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/general/social-media/25/04/44817229/chinese-tiktok-influencers-expose-cheap-nike-lululemon-suppliers-to-bypass-trump-tariffs">Chinese TikTok Influencers &#8216;Expose&#8217; Cheap Nike, Lululemon Suppliers To Bypass Trump Tariffs&nbsp;</a></li>
</ul>
Photo: Shutterstock

Earnings

Politics

Management

Economics

Blackstone President Warns Of Recession Risk Tied To Trump's Tariffs

Piper Sandler analyst Adam Maeder reiterates Abbott Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>) with a Overweight and raises the price target from $133 to $145.

Piper Sandler Reiterates Overweight on Abbott Laboratories, Raises Price Target to $145

Super Micro Computer (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>) has outperformed the market over the past 15 years by 10.23% on an annualized basis producing an average annual return of 20.51%. Currently, Super Micro Computer has a market capitalization of $18.42 billion. 
Buying $1000 In SMCI: If an investor had bought $1000 of SMCI stock 15 years ago, it would be worth $16,673.83 today based on a price of $31.03 for SMCI at the time of writing.
<h3>Super Micro Computer's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1744908365_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

SMCI

If You Invested $1000 In This Stock 15 Years Ago, You Would Have This Much Today

Piper Sandler analyst Crispin Love maintains Virtus Inv (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VRTS#NYSE">VRTS</a>) with a Overweight and lowers the price target from $216 to $211.

VRTS

Piper Sandler Maintains Overweight on Virtus Inv, Lowers Price Target to $211

<a href="https://www.semafor.com/article/04/17/2025/elliott-activist-ceo-change-hewlett-packard-enterprise" title="https://www.semafor.com/article/04/17/2025/elliott-activist-ceo-change-hewlett-packard-enterprise">https://www.semafor.com/article/04/17/2025/elliott-activist-ceo-change-hewlett-packard-enterprise</a>

'Activist seeks CEO Change At Hewlett Packard Enterprise' - Semafor

Piper Sandler analyst Scott Siefers maintains U.S. Bancorp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USB#NYSE">USB</a>) with a Overweight and lowers the price target from $49 to $48.

Piper Sandler Maintains Overweight on U.S. Bancorp, Lowers Price Target to $48

WIIM

BMRA

Biomerica shares are trading higher after the company announced its Fortel Kidney Disease Test has been approved for sale by the UAE Ministry of Health and Prevention.

Live On CNBC, Steve Weiss Announces Bought More UnitedHealth

Piper Sandler analyst Matthew Clark maintains Plumas (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLBC#NASDAQ">PLBC</a>) with a Overweight and lowers the price target from $60 to $59.

PLBC

Piper Sandler Maintains Overweight on Plumas, Lowers Price Target to $59

NNOX

NANO-X IMAGING shares are trading higher after the company announced it received FDA clearance for Nanox.ARC X

RBC Capital analyst Douglas Miehm maintains WELL Health Technologies (TSX:<a class="ticker" href="https://www.benzinga.com/stock/WELL#TSX">WELL</a>) with a Outperform and lowers the price target from C$7.5 to C$7.

TSX:WELL

RBC Capital Maintains Outperform on WELL Health Technologies, Lowers Price Target to C$7

Piper Sandler analyst Frank Schiraldi maintains Fulton Financial (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FULT#NASDAQ">FULT</a>) with a Neutral and lowers the price target from $22 to $20.

FULT

Piper Sandler Maintains Neutral on Fulton Financial, Lowers Price Target to $20

Piper Sandler analyst Stephen Scouten maintains FB Financial (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FBK#NYSE">FBK</a>) with a Overweight and lowers the price target from $60 to $58.

Piper Sandler Maintains Overweight on FB Financial, Lowers Price Target to $58

<figure class="wp-block-image size-large"><img decoding="async" src="https://thearorareport.com/wp-content/uploads/2025/04/2025-04-17_08h18_54.png" alt="" /></figure>
To gain an edge, this is what you need to know today.
<h4 class="wp-block-heading">Avoid The Common Investment Mistake</h4>
Please <a href="https://thearorareport.com/stock-market-chart-investor-mistake-no-fed-put-tlt-mc-04172025">click here</a> for an enlarged chart of iShares 20+ Year Treasury Bond ETF (TLT).
Note the following:
<ul>
<li>Countless investors and investment advisors are losing significant money because they are stuck in the orthodox thinking that long bonds are a safe haven.&nbsp;&nbsp;</li>
<li>The chart shows when TLT broke above zone 2 (resistance), there was aggressive buying in bonds, often considered a safe haven.</li>
<li>The chart shows bonds fell the next day below zone 2.</li>
<li>The chart shows bonds proceeded to fall through zone 3 (support) to the top band of zone 4 (support).</li>
<li>The chart shows bonds have bounced back into zone 3 (resistance).</li>
<li>RSI on the chart shows TLT is oversold. This contributed to the bounce.</li>
<li>The chart shows there is an RSI divergence.&nbsp; This indicates that TLT may fall again.</li>
<li>When the stock market recently began experiencing turbulence, countless investors and investment advisors rushed to buy long bonds.&nbsp; The reason is that they are stuck in academic and Wall Street orthodoxy that long bonds are a safe haven.&nbsp; The result of investors and investment advisors not being able to break out of the orthodox thinking is that they lost significant money on a so-called safe haven.&nbsp; The foregoing is clearly proven from the chart.</li>
<li>The chart shows when the Fed made an aggressive 50 bps rate cut last year.</li>
<li>The chart shows that TLT also broke out above the top band of zone 1 (resistance).&nbsp; At that time, believing that long bonds would go higher, countless investors and investment advisors bought long bonds.</li>
<li>The chart shows the contrary Arora call at that time that bonds will fall.  The chart shows that the our call has proven spot on, and investors who bought long bonds on the Fed's aggressive rate cut have experienced significant losses.  </li>
<li>Recognizing that many investors and investment advisors are not able to break out of the orthodox thinking, in every Morning Capsule, we publish a section titled "Traditional 60/40 Portfolio." </li>
<li>Initial jobless claims came at 215K vs. 225K consensus.</li>
</ul>
<ul>
<li>We have been writing there is no Fed put.  However, the market believed there was a Fed put.  Powell's statement goes against the market forecast.</li>
<li>President Trump blasted Powell in a post after Powell saying there is no Fed put.&nbsp; President Trump wrote, "The ECB is expected to cut interest rates for the 7th time, and yet, &#8216;Too Late&#8217; Jerome Powell of the Fed, who is always TOO LATE AND WRONG, yesterday issued a report which was another, and typical, complete &#8216;mess!&#8217;"</li>
<li>Powell has clearly angered President Trump.&nbsp; President Trump also posted, "Powell&#8217;s termination cannot come fast enough!"</li>
<li>As a heads up, if President Trump fires Powell, our Protection Band will likely be significantly raised.  </li>
<li>News about trade negotiations is very important for the markets.&nbsp; Here are the three pieces of news to focus on.
<ul>
<li>President Trump met with Japanese trade representatives and made good progress.</li>
<li>President Trump had a productive call with the President of Mexico.</li>
<li>Today, President Trump is meeting with Italy.</li>
</ul>
</li>
<li>Among earnings, the following are noteworthy:
<ul>
<li>The largest home builder DR Horton Inc (DHI) reported below consensus and is guiding below consensus.</li>
<li>The largest health insurer UnitedHealth Group Inc (UNH) reported earnings below consensus and guided below consensus.  UnitedHealth results highlight rising medical costs.</li>
<li>The largest semiconductor foundry Taiwan Semiconductor Manufacturing Company  (TSM) reported above consensus and is guiding above consensus.</li>
</ul>
</li>
<li>Eli Lilly And Co (LLY) reported Phase III data for orforglipron, an oral weight loss drug.  The weight loss is comparable to Wegovy and inline with Wall Street's expectations of 5% &#8211; 6% weight loss.  The pill is also highly effective for diabetes.  Effective, injectable weight loss drugs have been very popular.  The stock market has been waiting for an effective weight loss pill.  Eli Lilly's results show that a weight loss pill is almost here.  LLY stock is jumping 13% in the premarket.  LLY stock is trading at $829.12 as of this writing in the premarket.  As full disclosure, LLY is in our ZYX Buy Core Model Portfolio, long from $318.45.  There is also a signal in our ZYX Short for short selling Eli Lilly competitor Novo Nordisk A/S (NVO).</li>
</ul>
<h4 class="wp-block-heading">Europe</h4>
The European Central Bank (ECB) has cut three key interest rates by 25 bps.&nbsp; The rate cut appears to be influenced by the tariff decisions made by President Trump.
<h4 class="wp-block-heading">Magnificent Seven Money Flows</h4>
In the early trade, money flows are positive in Apple Inc (AAPL), Amazon.com, Inc. (AMZN), Alphabet Inc Class C (GOOG), Meta Platforms Inc (META), Microsoft Corp (MSFT), NVIDIA Corp (NVDA), and Tesla Inc (TSLA).
In the early trade, money flows are positive in SPDR S&amp;P 500 ETF Trust (SPY) and Invesco QQQ Trust Series 1 (QQQ).
<h4 class="wp-block-heading">Momo Crowd And Smart Money In Stocks</h4>
Investors can gain an edge by knowing money flows in SPY and QQQ.  Investors can get a bigger edge by knowing when smart money is buying stocks, gold, and oil.  The most popular ETF for gold is SPDR Gold Trust (GLD).  The most popular ETF for silver is iShares Silver Trust (SLV).  The most popular ETF for oil is United States Oil ETF (USO).
<h4 class="wp-block-heading">Bitcoin</h4>
Bitcoin is range bound.
<h4 class="wp-block-heading">Protection Band And What To Do Now</h4>
It is important for investors to look ahead and not in the rearview mirror.  Our proprietary Protection Band puts all of the data, all of the indicators, all of the news, all of the crosscurrents, all of the models, and all of the analysis in an analytical framework that is easily actionable by investors.
Consider continuing to hold good, very long term, existing positions. Based on individual risk preference, consider a protection band consisting of cash or Treasury bills or short-term tactical trades as well as short to medium term hedges and short term hedges. This is a good way to protect yourself and participate in the upside at the same time.
You can determine your protection bands by adding cash to hedges.&nbsp; The high band of the protection is appropriate for those who are older or conservative. The low band of the protection is appropriate for those who are younger or aggressive.&nbsp; If you do not hedge, the total cash level should be more than stated above but significantly less than cash plus hedges.
A protection band of 0% would be very bullish and would indicate full investment with 0% in cash.&nbsp; A protection band of 100% would be very bearish and would indicate a need for aggressive protection with cash and hedges or aggressive short selling.
It is worth reminding that you cannot take advantage of new upcoming opportunities if you are not holding enough cash.&nbsp; When adjusting hedge levels, consider adjusting partial stop quantities for stock positions (non ETF); consider using wider stops on remaining quantities and also allowing more room for high beta stocks.&nbsp; High beta stocks are the ones that move more than the market.
<h4 class="wp-block-heading">Traditional 60/40 Portfolio</h4>
Probability based risk reward adjusted for inflation does not favor long duration strategic bond allocation at this time.
Those who want to stick to traditional 60% allocation to stocks and 40% to bonds may consider focusing on only high quality bonds and bonds of five year duration or less.&nbsp; Those willing to bring sophistication to their investing may consider using bond ETFs as tactical positions and not strategic positions at this time.
The Arora Report is known for its accurate calls. The Arora Report correctly called the big artificial intelligence rally before anyone else, the new bull market of 2023, the bear market of 2022, new stock market highs right after the virus low in 2020, the virus drop in 2020, the DJIA rally to 30,000 when it was trading at 16,000, the start of a mega bull market in 2009, and the financial crash of 2008. Please click here to sign up for a free forever <a href="https://thearorareport.com/generate-wealth-newsletter-benzinga">Generate Wealth Newsletter</a>.

Long Ideas

Market Summary

Bonds

Broad U.S. Equity ETFs

Health Care

Opinion

Federal Reserve

Markets

Avoid The Mistake Countless Investors And Advisors Are Making, Oral Weight Loss Drug Is Almost Here

Piper Sandler analyst Andrew Liesch maintains Equity Bancshares (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EQBK#NYSE">EQBK</a>) with a Overweight and lowers the price target from $46 to $44.

EQBK

Piper Sandler Maintains Overweight on Equity Bancshares, Lowers Price Target to $44

Trump Media &amp; Technology Group Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DJT#NASDAQ">DJT</a>) saw its shares edge higher Thursday after the company sent a complaint to federal regulators, citing potential market manipulation <a href="https://www.benzinga.com/markets/equities/25/04/44832068/trump-media-technology-group-faces-106-million-short-bet-from-hedge-fund-as-shares-plunge-to-six-month-low" target="_blank" rel="noreferrer noopener">involving its stock.</a>
The memo, addressed to the U.S. Securities and Exchange Commission, raises concerns about unusual trading patterns and a foreign <a href="https://www.benzinga.com/pressreleases/25/04/g44862505/trump-media-alerts-sec-to-potential-manipulation-of-djt-stock">hedge fund&#8217;s large short position disclosure.</a>
In the Thursday letter, Trump Media &amp; Technology alleged that U.K.-based hedge fund Qube Research &amp; Technologies disclosed a nearly six-million share short position in DJT stock through a German filing.
The company questioned the lack of transparency around the timing and execution of these trades.
Trump Media &amp; Technology stated that despite the Qube filing, short interest in DJT shares remains relatively unchanged, hovering around 11 million shares as of Wednesday.
Also Read:<a target="_blank" href="https://www.benzinga.com/news/25/04/44850662/as-maga-yall-etfs-gain-traction-trump-media-unveils-values-based-investment-accounts" rel="noreferrer noopener"> As MAGA, YALL ETFs Gain Traction, Trump Media Unveils &#8216;Values-Based&#8217; Investment Accounts</a>
The company claims no U.S. exchange or regulatory authority has been able to verify when—or even if—Qube executed the trades associated with the disclosed position.
The firm argues that the lack of clarity, combined with DJT&#8217;s persistent presence on Nasdaq&#8217;s Regulation SHO Threshold List throughout much of 2024, may signal the presence of illegal naked short selling.
The complaint was also forwarded to FINRA, Nasdaq, and the New York Stock Exchange for review.
&#8220;We urge you to immediately investigate this suspicious trading and report your findings back to TMTG and any relevant civil and criminal authorities,&#8221; the company said.&nbsp;
The company emphasized that U.S. markets should operate with integrity and warned against conditions that resemble &#8220;a third-world casino.&#8221;
According to&nbsp;<a target="_blank" href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw" rel="noreferrer noopener">Benzinga Pro</a>, DJT stock has lost over 21% in the past year.
Price Action: DJT shares are trading higher by 11% to $21.94 at last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/government/regulations/25/04/44862662/trump-pressures-fed-as-ecb-delivers-7th-straight-rate-cut" target="_blank" rel="noreferrer noopener">Trump Pressures Fed As ECB Delivers 7th Straight Rate Cut</a></li>
</ul>
Photo: Shutterstock

Comments

Context Therapeutics

Notizie

Ultime notizie per Context Therapeutics (NASDAQ:CNTX) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO